Abstract
No public abstract is available from the verified source records.
Meiji Chen, Ge Shan, Zheng Xiang, Zhinan Yin
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Primary, adaptive, and acquired resistance to cancer immunotherapy
10.1016/j.cell.2017.01.017 · 2017
Understanding the tumor immune microenvironment (TIME) for effective therapy
10.1038/s41591-018-0014-x · 2018
Mechanisms of resistance to immune checkpoint inhibitors
10.1038/bjc.2017.434 · 2018
Interleukin-18 and IL-18 binding protein
10.3389/fimmu.2013.00289 · 2013
Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer
10.1158/1078-0432.ccr-06-0121 · 2006
IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy
10.1038/s41586-020-2422-6 · 2020
IL-18-mediated tumor immune evasion
2026
Durable antitumor response via an oncolytic virus encoding decoy-resistant IL-18
10.1136/jitc-2024-009716 · 2024
Gene-based delivery of immune-activating cytokines for cancer treatment
10.1016/j.molmed.2023.01.006 · 2023
IL-18 and IL-18BP: a unique dyad in health and disease
10.3390/ijms252413505 · 2024
Biological and clinical roles of IL-18 in inflammatory diseases
10.1038/s41584-023-01053-w · 2024
Interleukin-18 binding protein in immune regulation and autoimmune diseases
10.3390/biomedicines10071750 · 2022
Inflammasome components as new therapeutic targets in inflammatory disease
10.1038/s41577-024-01075-9 · 2025
IL-1 family cytokines in inflammation and immunity
10.1038/s41423-025-01358-8 · 2025
Weal and woe of interleukin-18 in the t cell therapy of cancer
10.1136/jitc-2024-010545 · 2025
Unlocking IL-18: a hidden key in cancer immunity
10.1016/j.smim.2025.101997 · 2025
Effect of IL-18 on expansion of gammadelta t cells stimulated by zoledronate and IL-2
2010
In the absence of a TCR signal IL-2/IL-12/18-stimulated γδ t cells demonstrate potent anti-tumoral function through direct killing and senescence induction in cancer cells
10.3390/cancers12010130 · 2020
IL-18 receptor marks functional CD8(+) t cells in non-small cell lung cancer
2017
IL18 receptor signaling regulates tumor-reactive CD8+ t-cell exhaustion via activation of the IL2/STAT5/mTOR pathway in a pancreatic cancer model
10.1158/2326-6066.cir-22-0398 · 2023
IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ t cells to the tumor microenvironment
10.1158/0008-5472.can-12-4366 · 2013
Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells
10.1016/j.bbmt.2014.01.006 · 2014
IL-12 regulates the expansion, phenotype, and function of murine NK cells activated by IL-15 and IL-18
10.1007/s00262-020-02553-4 · 2020
NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control
10.1016/j.cell.2018.01.004 · 2018
IL-18-primed NK cells recruit dendritic cells and potentiate tumor therapy mediated by PD-1 blockade
10.3389/fonc.2025.1533808 · 2025
Enhancement of phagocytosis and cytotoxicity in macrophages by tumor-derived IL-18 stimulation
10.5483/bmbrep.2014.47.5.152 · 2014
Inhibition of blood vessel formation in tumors by IL-18-polarized m1 macrophages
10.1111/gtc.12329 · 2016
Granzyme b-activated IL18 potentiates αβ and γδ CAR t cell immunotherapy in a tumor-dependent manner
10.1016/j.ymthe.2024.05.013 · 2024
Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive t-cell responses towards a type 1 pattern
10.1158/0008-5472.1063.65.3 · 2005
The dual effects of interleukin-18 in tumor progression
2007
Interleukin 18: friend or foe in cancer
2013
Interleukin-18 binding protein (IL-18BP): a long journey from discovery to clinical application
10.4110/in.2024.24.e1 · 2024
Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti–CTLA-4 in renal cell carcinoma
10.1172/jci.insight.184545 · 2025
IL-18 induces PD-1–dependent immunosuppression in cancer
10.1158/0008-5472.can-11-0993 · 2011
Cancer-induced immunosuppression: IL-18–elicited immunoablative NK cells
10.1158/0008-5472.can-11-3379 · 2012
Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer
10.18632/oncotarget.16281 · 2017
IL-18 enhances immunosuppressive responses by promoting differentiation into monocytic myeloid-derived suppressor cells
10.4049/jimmunol.1401282 · 2014
Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer
10.1016/j.jbo.2017.10.002 · 2017
Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment
10.1016/j.ccell.2018.02.007 · 2018
Interleukin-18 amplifies macrophage polarization and morphological alteration, leading to excessive angiogenesis
10.3389/fimmu.2018.00334 · 2018
Anti-PD1-IL18 immunoconjugate promotes effector t cell-mediated antitumor immunity
10.1136/jitc-2026-015090 · doi-reference
TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer
10.1038/s41590-023-01475-4 · doi-reference
Identification of a novel pyroptosis-related gene signature correlated with the prognosis of diffuse glioma patients
10.21037/atm-21-6011 · doi-reference
Elevated plasma interleukin-18 levels in head and neck squamous cell carcinoma: correlation with IL-18 binding protein but not ferritin
10.21873/anticanres.17482 · doi-reference
Nanobody-engineered bispecific IL-18 mimetics drive antitumor immunity by engaging CD8(+) t cell and evading IL-18BP in preclinical models
10.1016/j.ymthe.2025.07.004 · doi-reference
Engineered IL-18 variants with half-life extension and improved stability for cancer immunotherapy
10.1136/jitc-2025-011789 · doi-reference
Interleukin-18 (IL-18) engineered for half-life extension and resistance to IL-18 binding protein (IL-18BP) to enhance anti-cancer therapeutic potential
10.1016/j.cyto.2025.156979 · doi-reference
A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer
10.1158/1078-0432.ccr-07-4740 · doi-reference
IL-12, IL-15, and IL-18 pre-activated NK cells target resistant t cell acute lymphoblastic leukemia and delay leukemia developmentin vivo
10.1080/2162402x.2016.1274478 · doi-reference
Intratumoral gene transfer of mRNAs encoding IL12 in combination with decoy-resistant IL18 improves local and systemic antitumor immunity
10.1158/2326-6066.cir-22-0373 · doi-reference
Targeting highly attenuated IL-18 to PD-1 for enhanced anti-tumor activity
10.3389/fimmu.2025.1718321 · doi-reference
Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model
10.1038/s41423-021-00686-9 · doi-reference
Natural killer cells have a synergistic anti-tumor effect in combination with chemoradiotherapy against head and neck cancer
10.1016/j.jcyt.2022.05.004 · doi-reference
Optimization of natural killer cell expansion with k562-mbIL-18/−21 feeder cells and assurance of feeder cell-free products
10.3343/alm.2025.0168 · doi-reference
Expansion of cytotoxic natural killer cells in multiple myeloma patients using k562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21
10.1007/s00262-021-02982-9 · doi-reference
M-CSF induces the expression of a membrane-bound form of IL −18 in a subset of human monocytes differentiating in vitro toward macrophages
10.1002/eji.201142173 · doi-reference
How can we balance risk and benefit of interleukin-18 armored t cell therapies?
10.3389/ebm.2026.10938 · doi-reference
First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-t cells for relapsed/refractory b cell lymphomas
10.1016/j.omtn.2024.102308 · doi-reference
Enhanced CAR t-cell therapy for lymphoma after previous failure
10.1056/nejmoa2408771 · doi-reference
CD371-targeted CAR t cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia
10.1182/blood.2025029532 · doi-reference
IL-18-secreting multiantigen targeting CAR t cells eliminate antigen-low myeloma in an immunocompetent mouse model
10.1182/blood.2023022293 · doi-reference
IL-18–secreting CAR t cells targeting DLL3 are highly effective in small cell lung cancer models
10.1172/jci166028 · doi-reference
GMP-compliant manufacturing of TRUCKs: CAR t cells targeting GD2 and releasing inducible IL-18
10.3389/fimmu.2022.839783 · doi-reference
Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition
10.1080/19420862.2023.2236265 · doi-reference
Interleukin-18 in cancer immunology and immunotherapy
10.1080/14728222.2023.2287574 · doi-reference
IL-18 and VEGF-a trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia
10.3324/haematol.2022.282140 · doi-reference
IL-18 is a potent coinducer of IL-13 in NK and t cells: a new potential role for IL-18 in modulating the immune response
10.4049/jimmunol.162.9.5070 · doi-reference